English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Severe forms of psoriasis that are refractory to conventional therapies are often difficult to manage. The mammalian target of rapamycin (m TOR ) inhibitors potentially have versatile effects toward putative psoriatic pathologic pathways. Therefore, m TOR  inhibitors may offer a range of new therapeutic options for patients with psoriasis. We describe a 55‐year‐old male renal transplant patient with refractory psoriasis. We adjusted his antirejection regimen and put him on everolimus ( C ertican ® ; Novartis, Basel, Switzerland; a semisynthetic macrolide, belonging to the m TOR  inhibitors family) with low‐dose tacrolimus. This combination regimen maintained his graft function and successfully controlled his psoriasis. His skin lesions never recurred in the next 18 months. To our knowledge, this is the first report showing that the combination of everolimus and tacrolimus could be used to treat recalcitrant psoriasis. The relative benefit–risk profiles of such therapies worth further investigation.

Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis